Recruiting
Phase 2

A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2

Sponsor:

Seagen Inc.

Code:

NCT06003231

Conditions

Carcinoma, Squamous Cell of Head and Neck

Carcinoma, Non-Small-Cell Lung

Ovarian Neoplasms

Endometrial Neoplasms

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

disitamab vedotin

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information